A. Lièvre, P. Artru, M. Guiu, P. Laurent-puig, J. L. Merlin et al., The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011, Eur J Cancer, vol.49, pp.2126-2159, 2013.

F. Boissière-michot, E. Lopez-crapez, H. Frugier, M. L. Berthe, A. Ho-pun-cheung et al., KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment, Mod Pathol, vol.25, pp.731-740, 2012.

M. Stroun, J. Lyautey, C. Lederrey, A. Olson-sand, and P. Anker, About the possible origin and mechanism of circulating DNA apoptosis and active DNA release, Clin Chim Acta, vol.313, pp.139-181, 2001.

M. Van-der-vaart and P. J. Pretorius, Circulating DNA. Its origin and fluctuation, Ann N Y Acad Sci, vol.1137, pp.18-26, 2008.

S. Holdenrieder and P. Stieber, Apoptotic markers in cancer, Clin Biochem, vol.37, pp.605-622, 2004.

S. Holdenrieder and P. Stieber, Circulating apoptotic markers in the management of nonsmall cell lung cancer, Cancer Biomark, vol.6, pp.197-210, 2010.

T. Lecomte, A. Berger, F. Zinzindohoue, S. Micard, B. Landi et al., Detection of freecirculating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, vol.100, pp.542-550, 2002.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

A. R. Thierry, F. Mouliere, E. Messaoudi, S. Mollevi, C. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, pp.532-538, 2012.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, pp.224-248, 2014.

A. Didelot, S. K. Kotsopoulos, A. Lupo, D. Pekin, X. Li et al., Multiplex PicoliterDroplet Digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, pp.815-838, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299583

D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, and B. Vogelstein, Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations, Proc Natl Acad Sci, vol.100, pp.8817-8839, 2003.

A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. Eclov et al., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, pp.548-54, 2014.

F. Amant, M. Verheecke, I. Wlodarska, L. Dehaspe, P. Brady et al., Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing, JAMA Oncol, vol.1, pp.814-823, 2015.

I. Kinde, J. Wu, N. Papadopoulos, K. W. Kinzler, and B. Vogelstein, Detection and quantification of rare mutations with massively parallel sequencing, Proc Natl Acad Sci U S A, vol.108, pp.9530-9535, 2011.

S. El-messaoudi, F. Rolet, F. Mouliere, and A. R. Thierry, Circulating cell free DNA: preanalytical considerations, Clin Chim Acta, vol.424, pp.222-252, 2013.

G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, 2015.

M. P. Morelli, M. Overman, B. Kee, E. Vilar, V. Morris et al., Predictors of clonal evolution in metastatic colorectal cancer patients, J Clin Oncol, vol.33, issue.20, 2015.

J. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole et al., Gefitinib treatment in EGFR mutated caucasian NSCLC: circulatingfree tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, pp.1345-53, 2014.

M. Qiu, J. Wang, Y. Xu, X. Ding, M. Li et al., Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis, Cancer Epidemiol Biomarkers Prev, vol.24, pp.206-218, 2015.

J. Uchida, K. Kato, Y. Kukita, T. Kumagai, K. Nishino et al., Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA, Clin Chem, vol.61, pp.1191-1197, 2015.

N. Karachaliou, C. Mayo-de-las-casas, C. Queralt, I. De-aguirre, B. Melloni et al., Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial, JAMA Oncol, vol.1, pp.149-57, 2015.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012.

H. Kinugasa, K. Nouso, K. Miyahara, Y. Morimoto, C. Dohi et al., Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer, Cancer, 2015.

M. Sausen, J. Phallen, V. Adleff, S. Jones, R. J. Leary et al., Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat Commun, vol.6, p.7686, 2015.

K. L. Spindler, A. L. Appelt, N. Pallisgaard, R. F. Andersen, I. Brandslund et al., Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer, Int J Cancer, vol.135, pp.2984-91, 2014.

K. L. Spindler, N. Pallisgaard, and I. Vogelius, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan, Clin Cancer Res, vol.18, pp.1177-85, 2012.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, I. Skinner et al., Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC), J Clin Oncol, vol.32, issue.1, p.11015, 2014.

C. Tissot, A. C. Toffart, S. Villar, P. J. Souquet, P. Merle et al., Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy, J Clin Oncol, vol.33, issue.20, 2015.

H. Chen, H. Tu, Z. Q. Meng, Z. Chen, P. Wang et al., K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer, Eur J Surg Oncol, vol.36, pp.657-62, 2010.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, pp.1715-1737, 2015.

M. P. Morelli, M. J. Overman, A. Dasari, S. M. Kazmi, T. Mazard et al., Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment, Ann Oncol, vol.26, pp.731-737, 2015.

P. Laurent-puig, D. Pekin, C. Normand, S. K. Kotsopoulos, P. Nizard et al., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, pp.1087-97, 2015.

T. Mok, Y. Wu, J. S. Lee, C. Yu, V. Sriuranpong et al., Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy, Clin Cancer Res, vol.21, pp.3196-203, 2015.

G. R. Oxnard, C. P. Paweletz, Y. Kuang, S. L. Mach, A. O'connell et al., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, Clin Cancer Res, vol.20, pp.1698-705, 2014.

K. S. Thress, C. P. Paweletz, E. Felip, B. C. Cho, D. Stetson et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015.

C. Rolfo, M. Castiglia, D. Hong, A. R. Mertens, I. Baggerman et al., Liquid biopsies in lung cancer: the new ambrosia of researchers, Biochim Biophys Acta, vol.1846, pp.539-585, 2014.

C. Vibat, V. Melnikova, M. Minarik, B. Belsanova, S. Hancock et al., Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CCR) patients with resectable liver metastases, J Clin Oncol, vol.33, issue.20, 2015.